Clinical ResearchHeart FailureB-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction
Heart Failure
Under an Elsevier user license
open archive
Key Words
heart failure
natriuretic peptides
preserved ejection fraction
prognosis
Abbreviations and Acronyms
ACE
angiotensin-converting enzyme
ARB
angiotensin receptor blocker
BNP
B-type natriuretic peptide
CI
confidence interval
COPD
chronic obstructive pulmonary disease
HFPEF
heart failure with preserved ejection fraction
HR
hazard ratio
LVEF
left ventricular ejection fraction
NT-proBNP
N-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
Cited by (0)
The main COACH was supported by a large program grant (#2000Z003) from the Netherlands Heart Foundation. An additional unrestricted grant for measurement of B-type natriuretic peptide was obtained (in 2002) from Biosite Europe, France. Dr. van Veldhuisen has received board membership fees and/or travel expenses from Amgen, Johnson & Johnson, Novartis, Sorbent, Vifor, BG Medicine, and BioControl. Dr. Voors has received consultancy fees and/or research grants from Alere, Bayer, Cardio3 Biosciences, Celladon, Ceva, European Commission, Dutch Heart Foundation, Novartis, Servier, Torrent, and Vifor. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.